首頁 > 市場調查報告書 > 製藥

疼痛

市場調查報告書

商品編碼

1866553

疼痛管理藥物市場－2025-2030年預測

Pain Management Drugs Market - Forecasts from 2025 to 2030

出版日期: 2025年11月06日 | 出版商:

Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計到 2030 年，疼痛管理藥物市場將從 2025 年的 916.28 億美元成長到 1,164.12 億美元，複合年成長率為 4.90%。

疼痛管理市場是製藥業的重要組成部分，旨在滿足日益成長的有效止痛解決方案的需求。在全球人口老化、慢性病發病率上升以及外科手術數量增加的推動下，該市場預計將顯著成長。然而，替代性止痛設備的湧現對市場擴張構成了挑戰。

本報告檢驗了當前疼痛管理藥物市場的需求、供應和銷售趨勢，以及影響該市場的最新發展。報告全面分析了關鍵促進因素、阻礙因素和機遇，並詳細說明了區域產業趨勢、政策和法規，幫助相關人員深入了解法規結構和市場動態。

我們的競爭情報是基於廣泛的二手研究，包括產業協會調查、分析師報告、投資者報告、新聞稿和學術期刊，識別主要企業及其收入貢獻。市場規模採用自下而上和自上而下的方法計算，並透過全球疼痛管理藥物價值鏈相關人員的第一手資訊進行驗證。我們全面的市場分析整合了各種資訊來源和專有資料集，並運用資料三角測量技術，提供準確的市場區隔和預測。我們透過分析敘述、圖表和圖形呈現檢驗，以幫助讀者有效率地理解。預計2024年全球市場規模約785億美元，2030年將達1,123億美元，複合年成長率為6.2%。主要參與企業包括鴉片類藥物、非類固醇抗發炎藥、皮質類固醇、抗憂鬱症和抗驚厥藥的領先生產商。

主要亮點

老年人口不斷成長：預計到 2050 年，老齡人口將達到 15 億，這將推動對關節和慢性疾病疼痛管理藥物的需求。
慢性病流行：慢性病發病率不斷上升，到 2024 年將影響全球 60% 的成年人，這正在推動市場成長。
醫療保健支出：支出不斷成長，尤其是在北美地區，這為先進的疼痛管理解決方案提供了支援。
替代設備：止痛設備將在 2024 年佔據 8% 的市場佔有率，從而抑制藥品市場的成長。

成長要素

人口老化加劇（到2024年，65歲及以上成年人中將有20%患有慢性疼痛）顯著推動了對疼痛管理藥物的需求。類風濕性關節炎和癌症等慢性疾病的流行也促使人們需要標靶治療，例如非類固醇抗發炎藥和生物製藥。不斷成長的醫療費用支出（美國2024年的醫療保健支出將達到4.5兆美元）為獲得先進治療提供了支持。手術數量的增加（2024年全球手術量將增加6%）將推動術後止痛藥物的需求。

抑制因素

經皮神經電刺激（TENS）等止痛設備的日益普及，加劇了與傳統藥物的競爭，並對藥品銷售造成影響。歐盟和美國將於2024年收緊鴉片類藥物使用監管，將因成癮問題而限制處方箋。此外，研發新配方的高成本（平均高達10億美元）也成為製造商面臨的一大障礙。

細分分析

按藥物類型分類：非類固醇消炎劑（NSAIDs）將佔據主導地位，到2024年將佔40%的市場佔有率，這主要得益於其在肌肉骨骼疼痛治療中的廣泛應用。生技藥品在標靶慢性疼痛管理領域正經歷快速成長。

依適應症分類：慢性下背痛最常見，其次是癌症和術後疼痛。類風濕性關節炎的需求也上升。

按地區分類：北美佔 45% 的市場佔有率，這主要得益於美國的醫療保健支出和慢性病的流行。

區域分析

到2024年，北美將佔據45%的顯著市場佔有率，這主要得益於美國醫療保健領域的投資以及有效的疾病管理。亞太地區將以7.5%的複合年成長率成長，這主要得益於中國和印度慢性病病例的增加以及醫療基礎設施的改善。歐洲將憑藉其支持性的醫療政策保持成長勢頭。

本報告為業內人士提供關於市場趨勢、監管環境和競爭動態的關鍵洞察。報告探討了替代醫療器材和監管限制等挑戰，同時重點介紹了慢性病管理和創新製劑領域的機會。嚴謹的調查方法，結合一手和二手數據，確保了預測的可靠性，使相關人員能夠駕馭複雜的市場環境，並優先考慮在這一重要的醫藥領域的投資。

本報告的主要優勢：

深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略打入市場的潛力。
市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範及其影響、新產品開發、競爭影響

分析範圍

歷史資料（2022-2024 年）和預測資料（2025-2030 年）
成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
競爭對手定位、策略和市場佔有率分析
按業務板塊和地區（國家）分類的收入成長和預測分析
公司概況（策略、產品、財務資訊、關鍵趨勢等）

介紹
北美洲
- 美國
- 加拿大
- 墨西哥
南美洲
- 巴西
- 阿根廷
- 其他
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 其他
中東和非洲
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 其他
亞太地區
- 中國
- 日本
- 印度
- 韓國
- 台灣
- 泰國
- 印尼
- 其他

第10章競爭格局與分析

主要企業和策略分析
市佔率分析
企業合併、協議、商業合作
競爭對手儀錶板

第11章：公司簡介

Novartis AG
Eli Lilly and Company
Pfizer Inc.
GlaxoSmithKline plc
Merck & Co., Inc.
Sanofi SA
Abbott Laboratories
Johnson & Johnson
Endo International PLC
Viatris Inc.
Purdue Pharma LP
Teva Pharmaceuticals Industries Ltd.

第12章分析方法

簡介目錄

Product Code: KSI061612046

The Pain Management Drugs Market is projected to climb from USD 91.628 billion in 2025 to USD 116.412 billion by 2030, fueled by a 4.90% CAGR.

The pain management drugs market is a critical segment of the pharmaceutical industry, addressing the growing need for effective pain relief solutions. Driven by an aging global population, increasing prevalence of chronic diseases, and rising surgical procedures, the market is poised for significant growth. However, the availability of alternative pain relief devices poses a challenge to market expansion.

This research examines current trends in demand, supply, and sales, alongside recent developments shaping the pain management drugs market. It provides a comprehensive analysis of key drivers, restraints, and opportunities, detailing industry trends, policies, and regulations across geographical regions to equip stakeholders with insights into the regulatory framework and market dynamics.

Competitive intelligence identifies major industry players and their revenue contributions, derived from extensive secondary research, including industry association studies, analyst reports, investor presentations, press releases, and journals. Market size for the overall sector and key segments was determined using bottom-up and top-down methodologies, validated with primary inputs from stakeholders in the global pain management drugs value chain. Comprehensive market engineering integrated data from diverse sources and proprietary datasets, employing data triangulation for accurate market breakdown and forecasting. Insights are presented through analytical narratives, charts, and graphics for efficient comprehension. The global market was valued at approximately USD 78.5 billion in 2024 and is projected to reach USD 112.3 billion by 2030, growing at a CAGR of 6.2%. Key players profiled include those leading in the production of opioids, NSAIDs, corticosteroids, antidepressants, and anticonvulsants.

Key Highlights

Geriatric Population Growth: An aging population, reaching 1.5 billion by 2050, drives demand for pain management drugs for joint and chronic conditions.
Chronic Disease Prevalence: Rising cases of chronic diseases, affecting 60% of adults globally in 2024, fuel market growth.
Healthcare Expenditure: Increased spending, particularly in North America, supports advanced pain management solutions.
Alternative Devices: Pain relief devices, gaining 8% market share in 2024, restrain drug market growth.

Growth Drivers

The growing geriatric population, with 20% of adults over 65 experiencing chronic pain in 2024, significantly boosts demand for pain management drugs. The prevalence of chronic diseases, such as rheumatoid arthritis and cancer, drives the need for targeted therapies like NSAIDs and biologics. Rising healthcare expenditure, with the U.S. allocating USD 4.5 trillion to healthcare in 2024, supports access to advanced treatments. Increasing surgical procedures, up 6% globally in 2024, heighten demand for post-operative pain relief.

Restraints

The growing adoption of pain relief devices, such as TENS units, competes with pharmaceutical solutions, impacting drug sales. Stringent regulations on opioid use, tightened in the EU and U.S. in 2024, limit prescriptions due to addiction concerns. High development costs for new formulations, averaging USD 1 billion, pose barriers for manufacturers.

Segmentation Analysis

By Drug Type: NSAIDs dominate with a 40% share in 2024, driven by widespread use for musculoskeletal pain. Biologics grow rapidly for targeted chronic pain management.

By Indication: Chronic back pain leads, followed by cancer and post-operative pain, with rheumatoid arthritis gaining traction.

By Geography: North America holds a 45% share, driven by U.S. healthcare spending and chronic disease prevalence.

Regional Analysis

North America commands a significant 45% market share in 2024, bolstered by U.S. healthcare investments and effective disease management. Asia Pacific grows at a 7.5% CAGR, driven by rising chronic disease cases and healthcare infrastructure development in China and India. Europe sustains growth through supportive healthcare policies.

This report equips industry experts with critical insights into market trends, regulatory landscapes, and competitive dynamics. It highlights opportunities in chronic disease management and innovative formulations while addressing challenges from alternative devices and regulatory constraints. The rigorous methodology, blending primary and secondary data, ensures reliable projections, enabling stakeholders to navigate complexities and prioritize investments in this essential pharmaceutical sector.

Key Benefits of this Report:

Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

Historical data from 2022 to 2024 & forecast data from 2025 to 2030
Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
Competitive Positioning, Strategies, and Market Share Analysis
Revenue Growth and Forecast Assessment of segments and regions including countries
Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation

By Drug Type

Opioids
Nonsteroidal anti-inflammatory drugs (NSAIDs)
Corticosteroids
Acetaminophen
Antidepressants
Anticonvulsant drugs
Local Anaesthetics
Others

By Indication

Cancer Pain
Rheumatoid Arthritis
Chronic Back Pain
Post-Operative Pain
Migraine and Headache Disorders
Others

By Drug Delivery

Oral
Injectable
Topical
Transdermal
Inhalation
Others

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Specialty Pharmacies

By Geography

North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
United Kingdom
Germany
France
Italy
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
Japan
India
South Korea
Taiwan
Thailand
Indonesia
Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter's Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. PAIN MANAGEMENT DRUGS MARKET BY DRUG TYPE

5.1. Introduction
5.2. Opioids
5.3. Nonsteroidal anti-inflammatory drugs (NSAIDs)
5.4. Corticosteroids
5.5. Acetaminophen
5.6. Antidepressants
5.7. Anticonvulsant drugs
5.8. Local Anaeshtehtics
5.9. Others

6. PAIN MANAGEMENT DRUGS MARKET BY INDICATION

6.1. Introduction
6.2. Cancer Pain
6.3. Rheumatoid Arthritis
6.4. Chronic Back Pain
6.5. Post-Operative Pain
6.6. Migraine and Headache Disorders
6.7. Others

7. PAIN MANAGEMENT DRUGS MARKET BY DRUG DELIVERY

7.1. Introduction
7.2. Oral
7.3. Injectable
7.4. Topical
7.5. Transdermal
7.6. Inhalation
7.7. Others

8. PAIN MANAGEMENT DRUGS MARKET BY DISTRIBUTION CHANNEL

8.1. Introduction
8.2. Hospital Pharmacies
8.3. Retail Pharmacies
8.4. Online Pharmacies
8.5. Specialty Pharmacies

9. PAIN MANAGEMENT DRUGS MARKET BY GEOGRAPHY

9.1. Introduction
9.2. North America
- 9.2.1. USA
- 9.2.2. Canada
- 9.2.3. Mexico
9.3. South America
- 9.3.1. Brazil
- 9.3.2. Argentina
- 9.3.3. Others
9.4. Europe
- 9.4.1. United Kingdom
- 9.4.2. Germany
- 9.4.3. France
- 9.4.4. Italy
- 9.4.5. Spain
- 9.4.6. Others
9.5. Middle East and Africa
- 9.5.1. Saudi Arabia
- 9.5.2. UAE
- 9.5.3. Others
9.6. Asia Pacific
- 9.6.1. China
- 9.6.2. Japan
- 9.6.3. India
- 9.6.4. South Korea
- 9.6.5. Taiwan
- 9.6.6. Thailand
- 9.6.7. Indosneisa
- 9.6.8. Others